Buy Hold Sell: 5 of your most popular ASX stocks (and 2 big buys)

Neuren Pharmaceuticals (ASX: NEU)

Henry Jennings: It's a little bit left-field, and it has been quite volatile. It's a stock called Neuren Pharmaceuticals and they are a very niche kind of orphan drug designation in the US. They've got one treatment out there, which they've licensed to a US company called Acadia, and they've got milestone payments. They've got upfront payments. They get a royalty stream. They've got $360 million in cash. It's capitalised at 1.5, 1.6 billion.

It is quite volatile. They do have a new drug coming, NNZ-2591, which they've got trials, results coming later this year, which could be a game changer for them again. They're chock-full of cash. They're doing a buyback, which is good. It is run on the smell of an oily rag. It's not another Opthea. That's tarred the sector to some extent.

Grady Wulff: It's been tough.

Henry Jennings: It's been tough, and that funding mechanism is not the same. The drug, Daybue, is in circulation. It is being sold in America. Good sales. Acadia doing well with that. My only reservation is that it is a very small market in the US. It gets bigger as you expand to the rest of the world, but it does cost $400,000 US per year. That's a lot of money.

Someone's got to pay for that. Insurance companies are paying for that, obviously, or hopefully, insurance companies are paying for it. But it is huge. It makes a massive difference to the quality of life for these poor kids that have these rare syndromes. The new drug will expand that, diversify it if it gets approval, if the trials are successful. It's got a lot of cash, good management. I've met Jon Pilcher a couple of times, talked to him. I like this one. It has been volatile, but it could double this year.

Grady Wulff: I will disclose I'm a happy Neuren shareholder, as well, so...

Henry Jennings: Oh, there you go. Preaching to the converted.